Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy Novel Treatment...
Service will be available to clinicians and healthcare providers to support patient assessments and diagnosis Scottish Brain Sciences (SBS) has ...
T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovati...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
UCB and Biogen Inc.announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS G...
Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has knowhow in vaccine conjugation a...
As biotech companies navigate increasingly complex pathways from scientific discovery to commercial success, the importance of location, expertise, and eco...
-Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, announced an alliance with bit.bio to create a comp...
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease The US Food and Drug Administration (FDA) has granted p...
Cornerstone Robotics ("CSR"), a leading global innovator in surgical robotics based in Hong Kong, China, is pleased to announce its Sentire® Endoscop...
Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal ant...
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obef...
AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract...
European Medicines Agency (EMA) has adopted a positive opinion recommending approval of nerandomilast for the treatment of idiopathic pulmonary fibrosis ...
© 2026 Biopharma Boardroom. All Rights Reserved.
